95 related articles for article (PubMed ID: 7747708)
1. Evaluation of the combination of vinblastine and quinidine in patients with metastatic renal cell carcinoma. A phase I study.
Agarwala SS; Bahnson RR; Wilson JW; Szumowski J; Ernstoff MS
Am J Clin Oncol; 1995 Jun; 18(3):211-5. PubMed ID: 7747708
[TBL] [Abstract][Full Text] [Related]
2. Phase I-II study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma.
Warner E; Tobe SW; Andrulis IL; Pei Y; Trachtenberg J; Skorecki KL
Am J Clin Oncol; 1995 Jun; 18(3):251-6. PubMed ID: 7747714
[TBL] [Abstract][Full Text] [Related]
3. Vinblastine in metastatic renal cell carcinoma: EORTC phase II trial 30882. The EORTC Genitourinary Group.
Fosså SD; Droz JP; Pavone-Macaluso MM; Debruyne FJ; Vermeylen K; Sylvester R
Eur J Cancer; 1992; 28A(4-5):878-80. PubMed ID: 1524914
[TBL] [Abstract][Full Text] [Related]
4. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.
Samuels BL; Hollis DR; Rosner GL; Trump DL; Shapiro CL; Vogelzang NJ; Schilsky RL
Clin Cancer Res; 1997 Nov; 3(11):1977-84. PubMed ID: 9815587
[TBL] [Abstract][Full Text] [Related]
5. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma.
Motzer RJ; Lyn P; Fischer P; Lianes P; Ngo RL; Cordon-Cardo C; O'Brien JP
J Clin Oncol; 1995 Aug; 13(8):1958-65. PubMed ID: 7636536
[TBL] [Abstract][Full Text] [Related]
7. Treatment of renal cell carcinoma with alpha (human leukocyte) interferon and vinblastine in combination: a phase I-II trial.
Figlin RA; deKernion JB; Maldazys J; Sarna G
Cancer Treat Rep; 1985 Mar; 69(3):263-7. PubMed ID: 3978656
[TBL] [Abstract][Full Text] [Related]
8. A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).
Bates S; Kang M; Meadows B; Bakke S; Choyke P; Merino M; Goldspiel B; Chico I; Smith T; Chen C; Robey R; Bergan R; Figg WD; Fojo T
Cancer; 2001 Sep; 92(6):1577-90. PubMed ID: 11745237
[TBL] [Abstract][Full Text] [Related]
9. A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinoma.
Small EJ; Frye JW; Wilkinson MJ; Carroll PR; Ernest ML; Stagg RJ
Cancer; 1994 Jun; 73(11):2803-7. PubMed ID: 8194022
[TBL] [Abstract][Full Text] [Related]
10. An outpatient phase II study of subcutaneous interleukin-2 and interferon-alpha-2b in combination with intravenous vinblastine in metastatic renal cell cancer.
Pectasides D; Varthalitis J; Kostopoulou M; Mylonakis A; Triantaphyllis D; Papadopoulou M; Dimitriadis M; Athanassiou A
Oncology; 1998; 55(1):10-5. PubMed ID: 9428369
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of vinblastine plus dipyridamole in advanced renal cell carcinoma. A Hoosier Oncology Group Study.
Murphy BR; Rynard SM; Pennington KL; Grosh W; Loehrer PJ
Am J Clin Oncol; 1994 Feb; 17(1):10-3. PubMed ID: 8311000
[TBL] [Abstract][Full Text] [Related]
12. Vinblastine and estramustine phosphate in metastatic renal cell carcinoma: a phase II trial of the Fox Chase Network.
Haas NB; Giantonio BJ; Litwin S; Minniti CJ; Fox S; Yeslow G; Reilly R; Nahum K; Greenberg R; Halbherr T; Hudes GR
Cancer; 2003 Nov; 98(9):1837-41. PubMed ID: 14584064
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine.
Braybrooke JP; Vallis KA; Houlbrook S; Rockett H; Ellmén J; Anttila M; Ganesan TS; Harris AL; Talbot DC
Cancer Chemother Pharmacol; 2000; 46(1):27-34. PubMed ID: 10912574
[TBL] [Abstract][Full Text] [Related]
14. Combined treatment with low-dose interferon plus vinblastine is associated with less toxicity than conventional interferon monotherapy in patients with metastatic renal cell carcinoma.
Tsavaris N; Skarlos D; Bacoyiannis C; Aravantinos G; Kosmas C; Retalis G; Panopoulos C; Vadiaka M; Dimitrakopoulos A; Kostantinidis K; Mitropoulos D; Bougas D; Pantazopoulos D; Kosmidis P
J Interferon Cytokine Res; 2000 Aug; 20(8):685-90. PubMed ID: 10954911
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma.
Berlin J; King AC; Tutsch K; Findlay JW; Kohler P; Collier M; Clendeninn NJ; Wilding G
Invest New Drugs; 1994; 12(2):137-41. PubMed ID: 7860231
[TBL] [Abstract][Full Text] [Related]
16. Vinblastine and erythromycin: an unrecognized serious drug interaction.
Tobe SW; Siu LL; Jamal SA; Skorecki KL; Murphy GF; Warner E
Cancer Chemother Pharmacol; 1995; 35(3):188-90. PubMed ID: 7805175
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of five-day continuous infusion of vinblastine in patients with metastatic renal-cell carcinoma.
Crivellari D; Tumolo S; Frustaci S; Galligioni E; Figoli F; Lo Re G; Veronesi A; Monfardini S
Am J Clin Oncol; 1987 Jun; 10(3):231-3. PubMed ID: 3591744
[TBL] [Abstract][Full Text] [Related]
18. Camptothecin analogues and vinblastine in the treatment of renal cell carcinoma: an in vivo study using a human orthotopic renal cancer xenograft.
El-Galley R; Keane TE; Sun C
Urol Oncol; 2003; 21(1):49-57. PubMed ID: 12684128
[TBL] [Abstract][Full Text] [Related]
19. A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma.
Bates SE; Bakke S; Kang M; Robey RW; Zhai S; Thambi P; Chen CC; Patil S; Smith T; Steinberg SM; Merino M; Goldspiel B; Meadows B; Stein WD; Choyke P; Balis F; Figg WD; Fojo T
Clin Cancer Res; 2004 Jul; 10(14):4724-33. PubMed ID: 15269145
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of vinblastine in advanced ovarian carcinoma. A Gynecologic Oncology Group study.
Sutton GP; Blessing JA; Adelson MD; Hanjani P
Invest New Drugs; 1990 Nov; 8(4):377-9. PubMed ID: 2084071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
